These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 12911939)

  • 1. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors.
    Aref S; Goda T; El-Sherbiny M
    Hematology; 2003 Aug; 8(4):221-8. PubMed ID: 12911939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Soluble syndecan-1 levels in different plasma cell dyscrasias].
    Jánosi J; Sebestyén A; Mikala G; Petö M; Jákó J; Domján G; Németh J; Kis Z; Kopper L; Vályi-Nagy I
    Orv Hetil; 2005 Jan; 146(4):165-8. PubMed ID: 15751511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
    Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
    Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
    Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
    Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival.
    Lovell R; Dunn JA; Begum G; Barth NJ; Plant T; Moss PA; Drayson MT; Pratt G;
    Br J Haematol; 2005 Aug; 130(4):542-8. PubMed ID: 16098068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Syndecan-1 (CD138): an immunohistochemical marker of plasma cell tumors].
    Fakan F; Boudová L; Hejda C
    Cesk Patol; 2002 Jan; 38(1):33-6. PubMed ID: 11933459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
    Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
    Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum syndecan-1: a new independent prognostic marker in multiple myeloma.
    Seidel C; Sundan A; Hjorth M; Turesson I; Dahl IM; Abildgaard N; Waage A; Borset M
    Blood; 2000 Jan; 95(2):388-92. PubMed ID: 10627439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble syndecan-1 levels in different plasma cell dyscrasias and in different stages of multiple myeloma.
    Jánosi J; Sebestyén A; Mikala G; Németh J; Kiss Z; Vályi-Nagy I
    Haematologica; 2004 Mar; 89(3):370-1. PubMed ID: 15020284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
    Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
    Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble syndecan-1 promotes growth of myeloma tumors in vivo.
    Yang Y; Yaccoby S; Liu W; Langford JK; Pumphrey CY; Theus A; Epstein J; Sanderson RD
    Blood; 2002 Jul; 100(2):610-7. PubMed ID: 12091355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The significance of soluble CD138 in diagnosis of monoclonal gammopathies.
    Maisnar V; Tousková M; Tichý M; Krejsek J; Chrobák L; Voglová J; Malý J
    Neoplasma; 2006; 53(1):26-9. PubMed ID: 16416009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer.
    Joensuu H; Anttonen A; Eriksson M; Mäkitaro R; Alfthan H; Kinnula V; Leppä S
    Cancer Res; 2002 Sep; 62(18):5210-7. PubMed ID: 12234986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
    Andersen NF; Standal T; Nielsen JL; Heickendorff L; Borset M; Sørensen FB; Abildgaard N
    Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The expression, secretion and regulation of membrane-soluble syndecan-1 in human multiple myeloma cells].
    Li X; Lu Z; Klein B
    Zhonghua Xue Ye Xue Za Zhi; 2000 Nov; 21(11):572-6. PubMed ID: 11225246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relative study of soluble syndecan-1 and prognosis of patients with multiple myeloma].
    Li X; Zhang X; Lu Z; Klein B
    Zhonghua Xue Ye Xue Za Zhi; 2001 Jun; 22(6):303-5. PubMed ID: 11877089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma.
    Dhodapkar MV; Kelly T; Theus A; Athota AB; Barlogie B; Sanderson RD
    Br J Haematol; 1997 Nov; 99(2):368-71. PubMed ID: 9375756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of soluble syndecan-1 in Hodgkin's lymphoma.
    Vassilakopoulos TP; Kyrtsonis MC; Papadogiannis A; Nadali G; Angelopoulou MK; Tzenou T; Dimopoulou MN; Siakantaris MP; Kontopidou FN; Kalpadakis C; Kokoris SI; Dimitriadou EM; Tsaftaridis P; Pizzolo G; Pangalis GA
    Anticancer Res; 2005; 25(6C):4743-6. PubMed ID: 16334170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum syndecan-1 in patients with newly diagnosed monoclonal proteinemia.
    Schaar CG; Vermeer HJ; Wijermans PW; Huisman W; le Cessie S; Kluin-Nelemans HC
    Haematologica; 2005 Oct; 90(10):1437-8. PubMed ID: 16219583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Determination proliferative activity of myeloma cells in histologic material].
    Fabian P; Kren L; Nenutil R
    Cesk Patol; 2004 Apr; 40(2):46-9. PubMed ID: 15233016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.